Literature DB >> 1601024

The low-pressure duct perfusion model of acute pancreatitis.

A L Widdison1, C Alvarez, H A Reber.   

Abstract

The low-pressure duct perfusion model reliably produces acute pancreatitis in cats. The main pancreatic duct is made permeable in one of several ways: the perfusion of glycodeoxycholic acid along the main pancreatic duct, the administration of intragastric ethanol, the stimulation of pancreatic secretion into an obstructed duct, or the creation of acute hypercalcemia. Active pancreatic enzymes are then perfused through the main pancreatic duct via a catheter inserted into the duct in the tail of the gland, and acute edematous pancreatitis results. Simultaneous infusion of 16,16-dimethylprostaglandin E2 converts acute edematous into acute hemorrhagic pancreatitis. Histologically, the characteristic changes of human acute pancreatitis are manifest 24 h later: necrosis, polymorphonuclear leukocyte infiltrate, hemorrhage and edema.

Entities:  

Mesh:

Year:  1992        PMID: 1601024     DOI: 10.1159/000129239

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  5 in total

Review 1.  Infected pancreatic necrosis.

Authors:  C Bassi
Journal:  Int J Pancreatol       Date:  1994-08

2.  Pathogenesis of pancreatic infection.

Authors:  A L Widdison
Journal:  Ann R Coll Surg Engl       Date:  1996-07       Impact factor: 1.891

Review 3.  Animal models of pancreatitis: can it be translated to human pain study?

Authors:  Jing-Bo Zhao; Dong-Hua Liao; Thomas Dahl Nissen
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

4.  Review of experimental animal models of acute pancreatitis.

Authors:  Kim Hue Su; Christine Cuthbertson; Christopher Christophi
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

5.  Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis.

Authors:  A L Widdison; N D Karanjia; H A Reber
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.